Insights Accelerated. Foresight Delivered.

 

Xceleron’s analytical power accelerates your development program, saves you time and money, and moves your product forward with confidence.

 

What We Do

Xceleron is a world leader in the use of Accelerator Mass Spectrometry (AMS) analytical technology in pharmaceutical, food technology and crop protection applications.

Our primary business is in pharmaceutical research and development. Since 1998 we have been helping to design preclinical and clinical investigations around the unique analytical features of AMS, now a widely used and valuable tool in the quest for improved R&D efficiency. Smart use of AMS allows analytical challenges to be taken off the critical path by supporting time- and cost-efficient investigations.

  • Pharmaceutical Services

    Xceleron can help you to design and implement preclinical and clinical fit-for-purpose investigations. Our clients regularly use us to meet commercial objectives associated with:

    • Proof-of-concept
    • Asset sale
    • Asset purchase
    • Drug approval

    Learn More »

  • IVPK Studies in Phase II/III

    Learn More »

Xceleron At A Glance

R&D

Dedicated to pharmaceutical R&D support

150

We’ve supported over 150 pharmaceutical companies

+20

20—30 client studies per year

+15

15—20 clients per year

50%

50% of our business is from repeat clients

+20,000

We process 20,000 to 30,000 samples annually

>95%

Over 95% of our AMS studies are conducted at a full therapeutic dose by intended therapeutic route

12

12 marketed drugs have used Xceleron AMS data

5/6

In 2013 the FDA approved 27 new drugs. 6 contained AMS data & 5 of those contained Xceleron data

Accelerating the development programs of clients worldwide

Technology and Expertise

AMS is a unique analytical platform because it does not suffer from matrix effects, can be applied across a broad range of compound types, including small molecule and biologics, and is exquisitely sensitive. Xceleron has developed proprietary approaches to analytical method validation and can apply AMS in a clinical setting that is very efficient.

Find out more about the power of AMS

R&D Efficiency

We have supported over 100 pharmaceutical and biotechnology companies in target research, preclinical development and clinical Phases 0, I and II/III.   Our use of the AMS analytical platform has enabled R&D teams to increase R&D efficiency and reach their commercial objectives.

Email us now or call us at +1 240 361 1900

© Xceleron 2016 All Rights Reserved.